"The U.S. Food and Drug Administration today approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
Type 2 diabetes affects about 24 million people and accounts for "...
Monotherapy and Combination Therapy
Limitations of Use
ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.
ONGLYZA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using ONGLYZA. [See WARNINGS AND PRECAUTIONS]
DOSAGE AND ADMINISTRATION
The recommended dosage of ONGLYZA is 2.5 mg or 5 mg once daily taken regardless of meals. ONGLYZA tablets must not be split or cut.
Dosage in Patients with Renal Impairment
No dosage adjustment for ONGLYZA is recommended for patients with mild renal impairment (creatinine clearance [CrCl] > 50 mL/min).
The dosage of ONGLYZA is 2.5 mg once daily (regardless of meals) for patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis (creatinine clearance [CrCl] ≤ 50 mL/min) [see CLINICAL PHARMACOLOGY and Clinical Studies]. ONGLYZA should be administered following hemodialysis. ONGLYZA has not been studied in patients undergoing peritoneal dialysis.
Because the dosage of ONGLYZA should be limited to 2.5 mg based upon renal function, assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter. Renal function can be estimated from serum creatinine using the Cockcroft-Gault formula or Modification of Diet in Renal Disease formula. [See CLINICAL PHARMACOLOGY.]
Dosage Adjustment with Concomitant Use of Strong CYP3A4/5 Inhibitors
The dosage of ONGLYZA is 2.5 mg once daily when coadministered with strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin). [See DRUG INTERACTIONS and CLINICAL PHARMACOLOGY.]
Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin
When ONGLYZA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia. [See WARNINGS AND PRECAUTIONS]
Dosage Forms And Strengths
- ONGLYZA (saxagliptin) 5 mg tablets are pink, biconvex, round, film-coated tablets with “5” printed on one side and “4215” printed on the reverse side, in blue ink.
- ONGLYZA (saxagliptin) 2.5 mg tablets are pale yellow to light yellow, biconvex, round, film-coated tablets with “2.5” printed on one side and “4214” printed on the reverse side, in blue ink.
ONGLYZA® (saxagliptin) tablets have markings on both sides and are available in the strengths and packages listed in Table 14.
Table 14: ONGLYZA Tablet Presentations
|Tablet Strength||Film-Coated Tablet Color/Shape||Tablet Markings||Package Size||NDC Code|
|5 mg||pink biconvex, round||“5” on one side and “4215” on the reverse, in blue ink||Bottles of 30||0003-4215-11|
|Bottles of 90||0003-4215-21|
|Bottles of 500||0003-4215-31|
|Blister of 100||0003-4215-41|
|2.5 mg||pale yellow to light yellow biconvex, round||“2.5” on one side and “4214” on the reverse, in blue ink||Bottles of 30||0003-4214-11|
|Bottles of 90||0003-4214-21|
Storage and Handling
Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].
Manufactured by: Bristol-Myers Squibb Company, Princeton, NJ 08543 USA. Marketed by: Bristol-Myers Squibb Company, Princeton, NJ 08543 and AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850.. Rev May 2013
Last reviewed on RxList: 6/13/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Onglyza Information
Onglyza - User Reviews
Onglyza User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.